雙特異性抗體引領癌症治療新時代，台灣生技公司崛起

By PR Newswire on 10 Dec 2024

PR Newswire (www.prnasia.com), a Cision company, is the premier global provider of media monitoring platforms and news distribution services that marketers, corporate communicators and investor relations professionals leverage to engage key audiences. Having pioneered the commercial news distribution industry since 1954, PR Newswire today provides end-to-end solutions to produce, distribute, target and measure text and multimedia content across traditional, digital, mobile and social channels. Combining the world's largest multi-channel content distribution and optimization network with comprehensive workflow tools and platforms, PR Newswire powers the stories of organizations around the world. PR Newswire serves tens of thousands of clients from offices in the Americas, Europe, Middle East, Africa and Asia-Pacific regions.

台北2024年12月10日 /美通社/ -- 全球藥品市場在新冠疫情後重回癌症治療領銜的時代。默沙東的單株抗體藥Keytruda吉舒達因其卓越療效，2023年銷售突破250億美金，穩居癌症藥品冠軍。然而，隨著其核心專利將於2028年到期，全球各大藥廠蓄勢待發，爭奪市場寶座。

雙特異性抗體成為新興焦點，因其設計可同時攻擊兩個靶點，突破傳統限制，呈現更佳療效與安全性。例如康方生物的Ivonescimab 係針對PD-1與VEGF雙靶點，在歐洲腫瘤醫學年會展示優於吉舒達的二期肺癌臨床結果。Summit Therapeutics在2022年以50億美金取得該藥授權。另外默沙東於今年11月斥資58.8億美元收購禮新醫藥的類似產品LM-299，顯示出雙特異性抗體的巨大潛力。